BDNF and Tau as biomarkers of severity in multiple sclerosis

Area of Science:

• Neuroscience
• Biomarker Discovery
• Neurology

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Identifying reliable biomarkers for MS diagnosis, severity, and progression is crucial for patient management.
• Serum levels of tau protein and brain-derived neurotrophic factor (BDNF) are being investigated for their potential roles in neurological conditions.

Purpose of the Study:

• To determine if serum tau and BDNF levels can serve as severity biomarkers in multiple sclerosis (MS).
• To investigate the relationship between serum tau and BDNF levels and different MS subtypes and severity scores.

Main Methods:

• Serum samples were collected from 74 patients with relapsing-remitting MS, 11 with secondary-progressive MS, and 88 healthy controls (aged 18-55).
• Total tau and BDNF levels were quantified using Western blot analysis.
• Statistical comparisons were made between MS patient groups and controls, and correlations with MS severity scores were examined.

Main Results:

• MS patients exhibited increased serum tau levels and decreased BDNF levels compared to controls.
• Serum tau levels peaked in patients with relapsing-remitting MS and were associated with lower Expanded Disability Status Scale scores.
• No significant difference in tau levels was observed between secondary-progressive MS patients and controls, or in the most severe MS cases.

Conclusions:

• BDNF shows promise as a diagnostic biomarker for MS but is not suitable for assessing disease severity or progression.
• Serum tau may play a more significant role in the progression of MS, particularly in earlier or less severe stages.
• Further research is warranted to fully elucidate the utility of tau as a biomarker for MS progression and severity.